Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has completed its first commercial delivery of hair growth products based on Follicopeptide® to Hårklinikken, a leading international provider of specialized hair and scalp treatments.              

The delivery marks an important step in Coegin's ongoing commercial roll-out and follows shortly after the Company's first commercial delivery to Gents. With Hårklinikken, Coegin strengthens its presence within the professional segment, where products are introduced through hair experts and clinics with a strong focus on science, results, and long-term customer relationships. 

The first delivery to Hårklinikken further validates Coegin's ability to supply multiple commercial partners in parallel, and confirms that the Company's production, logistics, and quality systems are fully aligned with professional market requirements.

"Delivering our first commercial batch to Hårklinikken is another key milestone for Coegin," says Jens Eriksson, CEO of Coegin Pharma. "Hårklinikken is a highly respected player with deep expertise in hair biology and treatment. Their decision to introduce products based on Follicopeptide is a strong endorsement of our science and our ability to meet the expectations of the professional market."   

"Following the successful pre-launch with Gents, this delivery shows that our commercial strategy is gaining real traction across different channels. Step by step, we are building a solid foundation for scalable growth together with strong partners," Eriksson adds.     

Coegin continues to work actively with both existing and new partners across selected markets, with the ambition to establish Follicopeptide as a leading science-based solution within premium and professional hair growth.

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com

Attached files